Direct Flow attracts $27m from Johnson & Johnson et al:
This article was originally published in Clinica
Executive Summary
Direct Flow Medical, a company developing a percutaneous heart valve replacement system, has bagged $27m in a series B financing co-led by Johnson & Johnson's investment arm and Foundation Medical Partners. Vantage Point Venture Partners and ePlanet - two new investors - also participated in the round, together with existing shareholders EDF Ventures, New Lead Venture Partners and Spray Venture Partners. Direct Flow's catheter-based system provides doctors with a minimally-invasive, transfemoral approach to replace diseased heart valve with a pericardial tissue implant. The Santa Rosa, California company initiated its European clinical study in September, following a first-in-man in Germany.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.